Protocol for bevacizumab purification using Ac-PHQGQHIGVSK-agarose by Barredo, Gabriela Romina et al.
Journal Pre-proof
Protocol for bevacizumab purification using Ac-PHQGQHIGVSK-agarose
Gabriela R. Barredo, Silvana L. Giudicessi, Marı́a C. Martı́nez
Ceron, Soledad L. Saavedra, Santiago Rodrı́guez, Lucas Filgueira
Risso, Rosa Erra-Balsells, Gustavo Mahler, Fernando Albericio,




To appear in: MethodsX
Received Date: 1 October 2019
Accepted Date: 6 December 2019
Please cite this article as: Barredo GR, Giudicessi SL, Martı́nez Ceron MC, Saavedra SL,
Rodrı́guez S, Filgueira Risso L, Erra-Balsells R, Mahler G, Albericio F, Cascone O, Camperi
SA, Protocol for bevacizumab purification using Ac-PHQGQHIGVSK-agarose, MethodsX
(2019), doi: https://doi.org/10.1016/j.mex.2019.12.010
This is a PDF file of an article that has undergone enhancements after acceptance, such as
the addition of a cover page and metadata, and formatting for readability, but it is not yet the
definitive version of record. This version will undergo additional copyediting, typesetting and
review before it is published in its final form, but we are providing this version to give early
visibility of the article. Please note that, during the production process, errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal
pertain.
© 2019 Published by Elsevier.
Protocol for bevacizumab purification using Ac-PHQGQHIGVSK-agarose 
 
Gabriela R. Barredoa,b, Silvana L. Giudicessia,b, María C. Martínez Cerona,b, Soledad L. Saavedraa,b, 
Santiago Rodríguezc, Lucas Filgueira Rissoc, Rosa Erra-Balsellsd,e, Gustavo Mahlerf, Fernando 
Albericiog,h, Osvaldo Casconea,b, Silvia A. Camperia,b*. 
 
aUniversidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Cátedra de Biotecnología. Junín 
956, 1113 Buenos Aires, Argentina. 
bCONICET-Universidad de Buenos Aires. Instituto de Nanobiotecnología (NANOBIOTEC). Facultad 
de Farmacia y Bioquímica. Junín 956, 1113 Buenos Aires, Argentina. 
cmAbxience SAU, Carlos Villate 5148, 1605, Munro, Buenos Aires, Argentina.  
dUniversidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Química 
Orgánica. Pabellón II. Ciudad Universitaria, 1428 Buenos Aires, Argentina. 
eCONICET, Universidad de Buenos Aires. Centro de Investigación en Hidratos de Carbono 
(CIHIDECAR). Facultad de Ciencias Exactas y Naturales Pabellón II. Ciudad Universitaria, 1428 
Buenos Aires, Argentina. 
fAGC Biologics. 22021 20th Avenue SE. Bothell, WA 98021. USA. 
gSchool of Chemistry & Physics, University of KwaZulu-Natal, Durban 4001, South Africa. 
hCIBER-BBN, Networking Centre on Bioengineering, Biomaterials and Nanomedicine, and 
Department of Organic Chemistry, University of Barcelona, 08028 Barcelona, Spain. 
 
Corresponding Author’s email address 
*Corresponding Author information: Silvia Andrea Camperi. Universidad de Buenos Aires. Facultad de 
Farmacia y Bioquímica. Cátedra de Biotecnología. Junín 956, 1113 Buenos Aires, Argentina. Phone: 
+541152874675. 
E-mail: scamperi@ffyb.uba.ar, scamperi55@gmail.com 
 







Bevacizumab is a monoclonal antibody, produced in CHO cells, used for the treatment of many human cancers. 









Nowadays its purification is achieved by affinity chromatography (AC) using protein A which is a very expensive 
ligand. On the other hand, the peptide Ac-PHQGQHIGVSK contained in the VEGF fragment binds bevacizumab 
with high affinity. This short peptide ligand has higher stability and lower cost than protein A and it can be 
prepared very easily by solid phase peptide synthesis. The present protocol describes the synthesis of Ac-
PHQGQHIGVSK-agarose and its use for affinity chromatography purification of bevacizumab from a clarified 
CHO cell culture. 
 Ac-PHQGQHIGVSK-agarose capacity and selectivity are equivalent to those of protein A matrices. 
 The peptide ligand shows a greater stability and lower cost. The lack of Trp, Met or Cys in the peptide ligand 
prevents its oxidation and extends the useful life of the chromatographic matrix. 
 Mild conditions used during chromatography preserved the integrity of bevacizumab. 
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Bevacizumab (trade name: AvastinTM) is an anti-vascular endothelial growth factor (anti-VEGF) that blocks the 
growth of tumor blood vessels. This monoclonal antibody (mAb), produced in CHO cells, is used for the treatment 
of many human cancers. Nowadays its purification is achieved by affinity chromatography (AC) using protein A, 
which is a high expensive ligand. Moreover, harsh elution conditions, that damage both the mAb and the protein 
ligand, are required to ensure bevacizumab recovery from the protein A affinity column. On the other hand, small 
peptides consisting of few amino acids represent ideal affinity chromatography ligands because they are much 
more physically and chemically stable than protein A and can be readily synthesized by standard chemistry in 
bulk amounts at a lower cost. Considering the bevacizumab binding site on the 85-Pro-His-Gln-Gly-Gln-His-Ile-
Gly-92 VEGF segment [1], a peptide ligand for bevacizumab purification by AC was designed [2]. Val-Ser-Lys 
was introduced as a spacer arm to facilitate bevacizumab interaction with the immobilized ligand. Ligand site-
directed immobilization on the agarose chromatographic support was ensured by the -amino group of the C-
terminal Lys and the acetylation of the N-terminus. The short peptide designed, Ac-PHQGQHIGVSK-NH2, has 
higher stability and lower cost than protein A and it can be prepared very easily by solid phase peptide synthesis. 
The present protocol describes the synthesis of the peptide Ac-PHQGQHIGVSK-NH2, its immobilization on 
agarose and the use of the Ac-PHQGQHIGVSK-agarose for affinity chromatography purification of bevacizumab 
from a clarified CHO cell culture. 
The peptide ligand shows higher stability and lower cost than protein A. The lack of Trp, Met or Cys in the peptide 
ligand prevents its oxidation and extends the useful life of the chromatographic matrix. Bevacizumab binding to 
the peptidyl-agarose is achieved using as adsorption buffer 20 mM sodium phosphate, 1 M (NH4)2SO4, pH 7.0. 
Bevacizumab adsorption at high ionic strength suggests that the binding is largely hydrophobic. The elution is 
performed quantitatively by removing the (NH4)2SO4 from the running buffer, thus weakening the hydrophobic 
forces that supported the binding of bevacizumab to the chromatographic matrix. The mild elution conditions 
preserve the integrity of both the peptide ligand and the mAb. Furthermore, Ac-PHQGQHIGVSK-agarose 
capacity and selectivity are equivalent to those of protein A matrices. 
 
Step 1: Ac-PHQGQHIGVSK-NH2 synthesis 
 
Material 
 Fluorenylmethyloxycarbonyl (Fmoc) protected amino acids 
 Rink-amide-MBHA resin (100-200 mesh, 0.67 meq/mg) 








 CH2Cl2  
 N-[(1 H-benzotriazol-1-yl)(dimethylamino)-methylene]-N-methylmethanaminium tetrafluoroborate N-oxide 
(TBTU) 
 N,N-diisopropylethylamine (DIEA) 
 Triisopropyl silane (TIS) 
 3,6-Dioxa-1,8-octanedithiol (DODT)  
 Trifluoroacetic acid (TFA) 
 Acetic anhydride (Ac2O) 
 20% piperidine in DMF (v/v) 
 TFA/TIS/H2O/DODT (92.5:2.5:2.5:2.5) 
 Acetonitrile (MeCN)/H2O (1:1) 
 Ethyl ether 
 Orbital shaker 
 Polypropylene column fitted with a polyethylene porous disk 
 
Procedure 
Note: Ac-PHQGQHIGVSK-NH2 is synthesized inside an efficient fume hood in polypropylene columns fitted 
with a polyethylene porous disk by solid phase Fmoc chemistry. 
1. Place 1 g Rink-Amide-MBHA resin (0.67 meq/g) in a solid phase reactor. 
Note: The amount of resin to use depends on the amount of peptide to be synthesized. Considering an 
overall yield of 75 %, 1 g of resin is used to obtain 0.5 mol of peptide. The ligand Ac-PHQGQHIGVSK-NH2 is 
synthesized in enough amount to prepare the affinity chromatographic media. Usually, the purity of the crude 
peptide (> 90%) is enough for using it without further purification. In the case of a lower purity, a purification 
by reverse phase C18 liquid chromatography is carried out. 
2. Wash the resin three times with CH2Cl2 and then with DMF. 
3. Incubate with 20% piperidine in DMF (v/v) (2 × 5 min) to remove the Fmoc group. 
4. Wash the resin with DMF (5 × 1 min). 
5.  Weight the Fmoc-Lys(Boc)-OH (3 eq) and TBTU (3 eq) into a dry tube and dissolve them in a minimum 
amount of DMF. 
6. Add the solution to the resin. 
7. Add DIEA (4 eq) dropwise to the resin and mix. 
8. Incubate the resin with agitation for 45 min at room temperature on an orbital shaker. 
9. Wash the resin with DMF (2 × 1 mL) and CH2Cl2 (2 × 1 mL) by filtration or decantation. 
10. To confirm the reaction coupling completion, test a small amount of resin (1-3 mg) with Kaiser test [3]. If 
positive, wash resin with DMF (2 × 1 min) and repeat coupling reaction with fresh reagents as indicated in 
steps 5-9. If negative, remove Fmoc group, wash the resin and couple the next Fmoc protected amino acid 
as indicated in steps 3-9. 
11. After peptide elongation, acetylate terminal proline by adding Ac2O (10 eq.) and DIC (10 eq.) in enough 
CH2Cl2 to make the swollen resin just mobile to agitation. 
12. Incubate during 1 h at room temperature. 
13. To test the completion of the acetylation reaction, perform the chloranil test with a small amount or resin (1-3 
mg) [4]. 
Note: The Kaiser test is a qualitative test for primary amines; hence, it cannot be reliably applied to the 
evaluation of Pro acetylation. For secondary amines the chloranil test is recommended. 
14. Remove side chain protecting groups and release the peptide from the resin by treatment with 15 mL of 
TFA/TIS/H2O/DODT (92:5.2:2.5:2.5) for 2 h. 
15. Remove the resin by filtration, and add the filtrates containing the peptide to a 10-fold volume of cold ethyl 
ether to precipitate it. 
16. Recover the precipitate by centrifugation (2,000–3,000 × g at 4 °C) during 10 min to ensure complete 
precipitation of the peptide. 
17. Wash the peptide with extra cold diethylether and recover the peptide again by centrifugation. 
18. Dissolve the peptide in MeCN/H2O (1:1) and lyophilize.  
 
Step 2: Affinity matrix synthesis [5] 
 
Material 
 Dry N-hydroxysuccinimide (NHS)-activated agarose 
 Dimethyl sulfoxide (DMSO) 
 Peptide Ac-PHQGQHIGVSK-NH2 
 Anhydrous triethylamine 
 Ethanolamine 
 Orbital shaker 










Note: Ac-PHQGQHIGVSK-agarose is synthesized in polypropylene columns fitted with a polyethylene 
porous disk. 
1. Place dry NHS-activated agarose (150 mg, that yields approximately 1 mL of hydrated resin) in a 
polypropylene column fitted with a polyethylene porous disk. 
2. Wash the resin with pure DMSO (3 × 5 min).  
3. Dissolve 50 mg of the peptide Ac-PHQGQHIGVSK-NH2 in 1 mL of DMSO and add to the NHS-agarose. 
Note: 50 mg of peptide Ac-PHQGQHIGVSK-NH2 is approximately 2-fold excess of the NHS group density in 
the agarose. 
4. Add to the gel/ligand slurry an amount of anhydrous triethylamine equimolar to the amount of peptide and 
gently shake for 2 h at room temperature.  
5. Filter the reaction mixture and save the filtrate for further analysis. 
6. Wash the gel three times with DMSO. 
7. Block any remaining unreacted groups by adding 50 μL of ethanolamine in 450 μL DMSO and then incubate 
for 30 min at room temperature. 
8. Wash the matrix successively with DMSO, DMSO/H2O (70:30, 50:50 and 30:70) and finally with degassed 
deionized H2O. 
 
Step 3: Evaluation of peptide immobilization on agarose 
 
Material 
 Absorption UV/VIS spectrophotometer 
 10 mm silica UV cell 
 
Procedure 
Peptide attachment is measured indirectly by quantifying the NHS released as a result of peptide 
immobilization. 
1. Measure the absorbance at 260 nm of the filtrate saved in step 2 (item 5). 
2. Calculate the NHS concentration, whose molar extinction coefficient () is 9600 M-1.cm-1 at 260 nm [6]. 
 
Step 4: Adsorption isotherms for bevacizumab binding to Ac-PHQGQHIGVSK-agarose 
 
Material 
 Absorption UV/VIS spectrophotometer 
 10 mm silica UV cell 
 Orbital shaker 
 20 mM sodium phosphate, 1 M (NH4)2SO4, pH 7.0 
 Labeled conical centrifuge micro tubes 
 Labeled polypropylene columns fitted with a polyethylene porous disk. 
 Pure bevacizumab solutions of known concentration 
 Bradford reagent 
 Thermomixer (Eppendorf) 
 Sigma Plot software (http://www.sigmaplot.com/products/sigmaplot/sigmaplot-details.php) 
 
Procedure  
Note: Adsorption isotherms are measured in stirred batch systems 
1. Equilibrate the affinity support, Ac-PHQGQHIGVSK-agarose, with 20 volumes of the adsorption buffer (20 
mM sodium phosphate, 1 M (NH4)2SO4, pH 7.0) in a chromatographic column. 
2. Add 50 μL of the chromatographic matrix to sequentially labeled conical centrifuge micro tubes, together with 
increasing volumes of pure bevacizumab solution and the amount of buffer necessary to reach a final 
volume of 1 mL. 
Note: To add the 50 μL of the chromatographic matrix to each tube, prepare a 1:1 suspension of the 
chromatographic matrix in adsorption buffer and while agitating measure 100 μL of the suspension with an 
automatic pipette with the tip cut at the end in order to increase its diameter. 
3. Prepare another set of labeled tubes with the same volume of protein stock solution and buffer but without 
matrix. 
4. Gently shake the tubes overnight at 25°C in Thermomixer to enable the system to reach its equilibrium. 
5. Separate the resin by filtration using labeled polypropylene columns fitted with a polyethylene porous disk. 
6. Measure the protein concentration in the filtrate with Bradford reagent. 
7. Determine free protein concentration at equilibrium (c*) with the first set of tubes and the total protein 
concentration at the beginning of the experiment (ct) with the second set of tubes. 
8. Calculate the amount of bevacizumab bound to the immobilized peptide at equilibrium, per unit of total 
chromatographic matrix volume (q*), as: 
q*=(ct-c*)1000/50 (1) 
9. To determine the maximum adsorption capacity for bevacizumab per volume of chromatographic matrix (qm) 
and the dissociation constant (Kd), non-lineal curve regression of the q* = f (c*) graph is performed with 












Step 5: Bevacizumab purification by peptide Ac-PHQGQHIGVSK-agarose affinity chromatography from 
the CHO cell culture 
 
Material 
 Adsorption buffer: 20 mM sodium phosphate, pH 7.0, 1 M (NH4)2SO4 
 A column containing 0.5 mL (0.5  2.5 cm) of Ac-PHQGQHIGVSK-agarose 
 Elution buffer: 20 mM sodium phosphate, pH 7.0 
 Absorption UV/VIS spectrophotometer 
 
Procedure  
1. Clarify the CHO cell culture containing bevacizumab by centrifugation or filtration. 
2. Add to the sample the amount of (NH4)2SO4 necessary to achieve a final concentration of 1 M. 
3. Equilibrate the chromatographic column containing Ac-PHQGQHIGVSK-agarose with 20 volumes of 
adsorption buffer. 
4. Load the column with CHO cell culture filtrate containing bevacizumab. 
Note: the amount of bevacizumab loaded to the column must be lower than the maximum capacity of the 
chromatographic matrix synthesized. 
5. Wash the column with adsorption buffer until the absorbance at 280 nm achieves the baseline value. 
6. Elute the bound protein by adding 20 mM sodium phosphate, pH 7.0. 
7. Measure total protein concentration with Bradford reagent using pure bevacizumab as the protein standard 
[8]. 
8. Measure bevacizumab concentration by HPLC using a protein A analytical column as per Zou et al. [9]. 
9. Perform sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) (12.5 % under reductive 





Peptide Ac-PHQGQHIGVSK-NH2 is easy to obtain with high purity by solid phase peptide synthesis. Ligand site-
directed immobilization on the NHS activated agarose is ensured by the -amino group of the C-terminal Lys and 
the acetylation of the N-terminus. The reaction is performed in organic solvent to prevent NHS ester hydrolysis, 
thus promoting higher immobilization yields [5]. When using Dry Pierce™ NHS-Activated Agarose, 17 µmol of 
peptide per mL of matrix was obtained with a maximum capacity of 38 mg of bevacizumab per mL of matrix. 
Similar results may be obtained using other NHS activated matrices such as NHS-activated Sepharose from GE 
Healthcare. 
Figure 1 shows the profile, together with the corresponding SDS-PAGE of the chromatographic fractions, using 
20 mM sodium phosphate, pH 7.0, 1 M (NH4)2SO4 as adsorption buffer and 20 mM sodium phosphate, pH 7.0 as 
elution buffer. The peptidyl-agarose adsorbs bevacizumab from the CHO cell culture filtrate while most 
contaminants pass through. Although the pass-through peak of the chromatogram is much higher than the elution 
peak, the protein concentration in both fractions are comparable. That is due to the contribution of the culture 
medium to the absorbance at 280 nm of the pass-through peak. 
 
Table 1 shows the purification obtained using buffers 20 mM sodium phosphate, 1 M (NH4)2SO4, pH 7.0, and 20 
mM sodium phosphate, pH 7.0, as adsorption and elution buffer respectively. The yield was 94% and the purity 
98%. 
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Figure 1. A) Bevacizumab purification from a CHO cell extract by affinity chromatography using Ac-
PHQGQHIGVSK-agarose. The adsorption buffer was 20 mM sodium phosphate pH 7.0, 1 M (NH4)2SO4. The 
elution was performed with 20 mM sodium phosphate buffer, pH 7.0. The arrow indicates the buffer change. B) 
SDS-PAGE gels under reducing conditions of the chromatographic fractions. Lanes: 1) Protein molecular weight 
marker (MW); 2) Pure bevacizumab standard; 3) Bevacizumab-producing CHO cell filtrate; 4) and 5) washing 











































Table 1 Purification chart of bevacizumab using Ac-PHQGQHIGVSK-agarose matrix. 







0.487 0.219 45.0 1.0 100 
Eluate 
fraction 
0.210 0.206 98.1 2.2 94.1 
aBevacizumab-producing CHO cell culture filtrate from mAbxience SAU. 
bProtein concentration determined by Bradford reagent. 
cBevacizumab concentration was determined by HPLC with a protein A column. 
dPurity defined as amount of bevacizumab as a fraction of total amount of protein. 
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